Total Payments
$4,926
2022 Payments
$1,247
Companies
45
Transactions
309
Medicare Patients
1,825
Medicare Billing
$166,090
Payment Breakdown by Category
Food & Beverage$4,843 (98.3%)
Education$82.65 (1.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,843 | 304 | 98.3% |
| Education | $82.65 | 5 | 1.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $925.87 | 64 | $0 (2022) |
| Amgen Inc. | $557.34 | 37 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $401.01 | 26 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $302.77 | 16 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $231.57 | 14 | $0 (2022) |
| Dexcom, Inc. | $224.16 | 14 | $0 (2022) |
| Lilly USA, LLC | $222.14 | 15 | $0 (2022) |
| Corcept Therapeutics | $209.90 | 11 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $128.06 | 7 | $0 (2020) |
| Insulet Corporation | $120.54 | 8 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $1,247 | 71 | Novo Nordisk Inc ($197.37) |
| 2021 | $679.84 | 37 | Novo Nordisk Inc ($155.19) |
| 2020 | $554.40 | 33 | Amgen Inc. ($134.96) |
| 2019 | $666.68 | 40 | Novo Nordisk Inc ($209.20) |
| 2018 | $802.79 | 53 | SANOFI-AVENTIS U.S. LLC ($258.27) |
| 2017 | $974.46 | 75 | Amgen Inc. ($143.30) |
All Payment Transactions
309 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/16/2022 | Amryt Pharma Holdings Ltd | MYCAPSSA (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Endocrinology | ||||||
| 11/15/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: DIABETES | ||||||
| 11/14/2022 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/02/2022 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $13.04 | General |
| Category: Endocrinology | ||||||
| 11/02/2022 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $13.04 | General |
| Category: Endocrinology | ||||||
| 10/24/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: Cardio-renal | ||||||
| 10/18/2022 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: Rare Disease | ||||||
| 10/17/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: Diabetes | ||||||
| 10/13/2022 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.55 | General |
| Category: Cardiology | ||||||
| 10/11/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/10/2022 | Tandem Diabetes Care, Inc. | t:slim X2 Insulin Pump with Control-IQ (Device) | Food and Beverage | Cash or cash equivalent | $13.61 | General |
| Category: Endocrinology | ||||||
| 10/06/2022 | Nevro Corp. | Omnia (Device) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Spinal Cord Stimulator | ||||||
| 10/05/2022 | IBSA Pharma Inc. | Tirosint (Drug), Licart, Flector | Food and Beverage | Cash or cash equivalent | $21.11 | General |
| Category: Endocrinology | ||||||
| 09/23/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/20/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Diabetes | ||||||
| 09/13/2022 | Amryt Pharma Holdings Ltd | MYCAPSSA (Drug) | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: Endocrinology | ||||||
| 09/13/2022 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $12.42 | General |
| Category: Diabetes | ||||||
| 09/08/2022 | Xeris Pharmaceuticals, Inc. | GVOKE PFS (Drug) | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: Diabetes | ||||||
| 08/30/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $28.06 | General |
| Category: Cardio-renal | ||||||
| 08/30/2022 | Lilly USA, LLC | BAQSIMI (Drug), LYUMJEV | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: Diabetes | ||||||
| 08/24/2022 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: Diabetes | ||||||
| 08/24/2022 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: Endocrinology | ||||||
| 08/22/2022 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: Diabetes | ||||||
| 08/18/2022 | Esperion Therapeutics, Inc. | NEXLIZET (Drug), NEXLETOL | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 08/16/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $13.89 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 7 | 591 | 954 | $153,140 | $57,872 |
| 2021 | 6 | 654 | 969 | $168,235 | $66,551 |
| 2020 | 6 | 580 | 699 | $119,284 | $41,667 |
Total Patients
1,825
Total Services
2,622
Medicare Billing
$166,090
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 245 | 435 | $102,660 | $39,896 | 38.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 85 | 97 | $15,423 | $6,231 | 40.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 29 | 29 | $10,527 | $3,727 | 35.4% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 159 | 274 | $8,220 | $2,633 | 32.0% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 44 | 90 | $8,550 | $2,491 | 29.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 11 | 11 | $3,476 | $1,485 | 42.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 18 | 18 | $4,284 | $1,409 | 32.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 227 | 404 | $95,344 | $40,667 | 42.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 149 | 191 | $30,369 | $12,377 | 40.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 55 | 55 | $19,965 | $7,408 | 37.1% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 39 | 75 | $7,125 | $2,194 | 30.8% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 145 | 205 | $6,150 | $1,991 | 32.4% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 39 | 39 | $9,282 | $1,915 | 20.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 184 | 232 | $54,752 | $19,554 | 35.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 128 | 152 | $24,168 | $8,945 | 37.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 52 | 52 | $18,876 | $6,119 | 32.4% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 56 | 56 | $13,328 | $4,422 | 33.2% |
| 83036 | Hemoglobin a1c level | Office | 2020 | 140 | 177 | $5,310 | $1,715 | 32.3% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2020 | 20 | 30 | $2,850 | $912.55 | 32.0% |
About Dr. Steven Wise, M.D
Dr. Steven Wise, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Dothan, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659327468.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Wise, M.D has received a total of $4,926 in payments from pharmaceutical and medical device companies, with $1,247 received in 2022. These payments were reported across 309 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($4,843).
As a Medicare-enrolled provider, Wise has provided services to 1,825 Medicare beneficiaries, totaling 2,622 services with total Medicare billing of $166,090. Data is available for 3 years (2020–2022), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Dothan, AL
- Active Since 05/25/2006
- Last Updated 01/24/2012
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1659327468
Products in Payments
- FARXIGA (Drug) $302.77
- EVENITY (Biological) $285.86
- Ozempic (Drug) $263.62
- Kerendia (Drug) $231.57
- Korlym (Drug) $209.90
- Victoza (Drug) $206.80
- SOLIQUA (Drug) $187.86
- TOUJEO (Drug) $170.17
- JARDIANCE (Drug) $145.50
- Prolia (Biological) $135.53
- Dexcom G5 Mobile CGM System (Device) $126.77
- Omnipod (Device) $120.54
- INVOKANA (Drug) $117.27
- ORENCIA (Biological) $110.75
- Rybelsus (Drug) $107.39
- GVOKE PFS (Drug) $104.08
- TRULICITY (Drug) $99.60
- Tymlos (Biological) $89.62
- Tresiba (Drug) $88.08
- Minimed 670G System (Device) $78.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.